Protective role of 3-oxypyridine derivatives in rats’ steroid-induced osteoporosis associated with reduced oxidative stress and recovery of nitric oxide formation

From the point of view of the mechanisms for the implementation of pathogenetic links in the development of steroid-induced osteoporosis considered in the paper, the increased risk of the oxidative stress in osteoblasts, as well as the development of the vessels endothelial dysfunction of the microcirculatory bloodstream in the bone tissue, are of particular interest. They lead to the impaired bone tissue trophism and progression of osteoporosis.

The aim of the study was research of the osteoprotective effects of a 3-hydroxypyridine derivatives composition on the model of steroid-induced osteoporosis.

Materials and methods. To model osteoporosis pathology, the animals (male Wistar rats) were injected with methylprednisolone (MP) at the dose of 5 mg/kg (intraperitoneally) every 5^th day for 5 weeks. Аs a non-selective blocker of NO synthase, L-NAME was used at the dose of 25 mg/kg (intraperitoneally). Derivatives of 3-hydroxypyridine (hereinafter referred to as composition No. 1) were administrated at the dose of 50 mg/kg (per os) In all experimental groups, the level of microcirculation and the bone mineral density, as well as the analysis of histomorphological and biochemical samples, were assessed.

Results. The study results showed that composition No. 1 (50 mg/kg) has an osteoprotective activity, effectively prevents a decrease in the level of the regional bone tissue microcirculation and in the development of an endothelial dysfunction. That makes it possible to increase the bone mineral density and to slow down the thinning of bone trabeculae. In addition, composition No. 1 (50 mg/kg) reduces the production of reactive oxygen species and increases the NO bioavailability.

Conclusion. The data obtained indicate that the studied composition of 3-hydroxypyridine derivatives is considered a promising compound for the prevention and treatment of steroid-induced osteoporosis.

1. Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018 Jul;61(1):7-16. https://doi.org/10.1007/s12020-018-1588-2

2. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012 Sep;41(3):595-611. https://doi.org/10.1016/j.ecl.2012.04.004

3. Cho SK, Sung YK. Update on Glucocorticoid Induced Osteoporosis. Endocrinol Metab (Seoul). 2021 Jun;36(3):536-43. https://doi.org/10.3803/EnM.2021.1021

4. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun. 2005 Apr 1;329(1):177-81. https://doi.org/10.1016/j.bbrc.2005.01.117

5. Swanson C, Lorentzon M, Conaway HH, Lerner UH. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology. 2006 Jul;147(7):3613-22. https://doi.org/10.1210/en.2005-0717

6. Jiang HT, Ran CC, Liao YP, Zhu JH, Wang H, Deng R, Nie M, He BC, Deng ZL. IGF-1 reverses the osteogenic inhibitory effect of dexamethasone on BMP9-induced osteogenic differentiation in mouse embryonic fibroblasts via PI3K/AKT/COX-2 pathway. J Steroid Biochem Mol Biol. 2019 Jul;191:105363. https://doi.org/10.1016/j.jsbmb.2019.04.012

7. Xie B, Zhou H, Liu H, Liao S, Zhou C, Xu D. Salidroside alleviates dexamethasone-induced inhibition of bone formation via transforming growth factor-beta/Smad2/3 signaling pathway. Phytother Res. 2022 Dec 25. https://doi.org/10.1002/ptr.7711

8. Korokin MV, Gudyrev OS, Lebedev PR, Kuzubova EV, Radchenko AI, Koklin IS, Taran EI, Kochkarov AA. Characteristics of the state of bone tissue in genetically modified mice with impaired enzymatic regulation of steroid hormone metabolism. Research Results in Pharmacology. 2022;8(4):157-66. https://doi.org/10.3897/rrpharmacology.8.98779

9. Tolba MF, El-Serafi AT, Omar HA. Caffeic acid phenethyl ester protects against glucocorticoid-induced osteoporosis in vivo: Impact on oxidative stress and RANKL/OPG signals. Toxicol Appl Pharmacol. 2017 Jun 1;324:26-35. https://doi.org/10.1016/j.taap.2017.03.021

10. Arafa EA, Elgendy NO, Elhemely MA, Abdelaleem EA, Mohamed WR. Diosmin mitigates dexamethasone-induced osteoporosis in vivo: Role of Runx2, RANKL/OPG, and oxidative stress. Biomed Pharmacother. 2023 May;161:114461. https://doi.org/10.1016/j.biopha.2023.114461. Ahead of Print

11. Fan ZQ, Bai SC, Xu Q, Li ZJ, Cui WH, Li H, Li XH, Zhang HF. Oxidative Stress Induced Osteocyte Apoptosis in Steroid-Induced Femoral Head Necrosis. Orthop Surg. 2021 Oct;13(7):2145-52. https://doi.org/10.1111/os.13127

12. Agidigbi TS, Kim C. Reactive Oxygen Species in Osteoclast Differentiation and Possible Pharmaceutical Targets of ROS-Mediated Osteoclast Diseases. Int J Mol Sci. 2019 Jul 22;20(14):3576. https://doi.org/10.3390/ijms20143576

13. Jeddi S, Yousefzadeh N, Kashfi K, Ghasemi A. Role of nitric oxide in type 1 diabetes-induced osteoporosis. Biochem Pharmacol. 2022 Mar;197:114888. https://doi.org/10.1016/j.bcp.2021.114888

14. Wimalawansa S, Chapa T, Fang L, Yallampalli C, Simmons D, Wimalawansa S. Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. J Bone Miner Res. 2000 Jun;15(6):1119-25. https://doi.org/10.1359/jbmr.2000.15.6.1119

15. Baecker N, Boese A, Schoenau E, Gerzer R, Heer M. L-arginine, the natural precursor of NO, is not effective for preventing bone loss in postmenopausal women. J Bone Miner Res. 2005 Mar;20(3):471-9. https://doi.org/10.1359/JBMR.041121

16. Shum LC, White NS, Mills BN, Bentley KL, Eliseev RA. Energy Metabolism in Mesenchymal Stem Cells During Osteogenic Differentiation. Stem Cells Dev. 2016 Jan 15;25(2):114-22. https://doi.org/10.1089/scd.2015.0193

17. Ekeuku SO, Mohd Ramli ES, Abdullah Sani N, Abd Ghafar N, Soelaiman IN, Chin KY. Tocotrienol as a Protecting Agent against Glucocorticoid-Induced Osteoporosis: A Mini Review of Potential Mechanisms. Molecules. 2022 Sep 9;27(18):5862. https://doi.org/10.3390/molecules27185862

18. Marcucci G, Domazetovic V, Nediani C, Ruzzolini J, Favre C, Brandi ML. Oxidative Stress and Natural Antioxidants in Osteoporosis: Novel Preventive and Therapeutic Approaches. Antioxidants (Basel). 2023 Feb 3;12(2):373. https://doi.org/10.3390/antiox12020373

19. Trunov KS, Danilenko AP, Pokrovsky VM, Peresypkina AA, Soldatov VO, Konovalova EA, Danilenko LM, Denisuk TA, Povetkin SV, Zhernakova NI. Endothelioprotective Impact of 2-Ethyl-3-Hydroxy-6-Methylpyridine Nicotinate. J Computation Theoretic Nanoscienc. 2020;17(9-10). P. 4746-50. https://doi.org/10.1166/jctn.2020.9372

20. Kesarev OG, Danilenko LM, Pokrovskii MV, Timokhina AS, Khovanskii AV. Study of dose-dependent effect of 2-ethyl-6-methyl-3 hydroxypyridine succinate on the contractile function of isolated rat heat. Research Results in Pharmacology. 2017;3(1): 3-9. https://doi.org/10.18413/2500-235X-2017-3-1-3-9

21. Sobolev MS, Faitelson AV, Gudyrev OS, Rajkumar DSR, Dubrovin GM, Anikanov AV, Koklina NU, Chernomortseva ES. Study of Endothelio- and Osteoprotective Effects of Combination of Rosuvastatin with L-Norvaline in Experiment. J Osteoporos. 2018 Nov 5;2018:1585749. https://doi.org/10.1155/2018/1585749

22. Liu M, Yang C, Chu Q, Fu X, Zhang Y, Sun G. Superoxide Dismutase and Glutathione Reductase as Indicators of Oxidative Stress Levels May Relate to Geriatric Hip Fractures’ Survival and Walking Ability: A Propensity Score Matching Study. Clin Interv Aging. 2022 Jul 12;17:1081-90. https://doi.org/10.2147/CIA.S370970

23. Mandal CC, Ganapathy S, Gorin Y, Mahadev K, Block K, Abboud HE, Harris SE, Ghosh-Choudhury G, Ghosh-Choudhury N. Reactive oxygen species derived from Nox4 mediate BMP2 gene transcription and osteoblast differentiation. Biochem J. 2011 Jan 15;433(2):393-402. https://doi.org/10.1042/BJ20100357

24. Yang X, Jiang T, Wang Y, Guo L. The Role and Mechanism of SIRT1 in Resveratrol-regulated Osteoblast Autophagy in Osteoporosis Rats. Sci Rep. 2019 Dec 5;9(1):18424. https://doi.org/10.1038/s41598-019-44766-3

25. Martiniakova M, Babikova M, Omelka R. Pharmacological agents and natural compounds: available treatments for osteoporosis. J Physiol Pharmacol. 2020 Jun;71(3). https://doi.org/10.26402/jpp.2020.3.01

26. Yamaguchi M, Uchiyama S. Preventive effect of zinc acexamate administration in streptozotocin-diabetic rats: Restoration of bone loss. Int J Mol Med. 2003 Nov;12(5):755-61.

27. Sun J, Chen W, Li S, Yang S, Zhang Y, Hu X, Qiu H, Wu J, Xu S, Chu T. Nox4 Promotes RANKL-Induced Autophagy and Osteoclastogenesis via Activating ROS/PERK/eIF-2α/ATF4 Pathway. Front Pharmacol. 2021 Sep 28;12:751845. https://doi.org/10.3389/fphar.2021.751845

28. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Prednisolone augments superoxide formation in porcine pulmonary artery endothelial cells through differential effects on the expression of nitric oxide synthase and NADPH oxidase. Br J Pharmacol. 2005 Jul;145(5):688-97. https://doi.org/10.1038/sj.bjp.0706235

29. Chen L, Wang G, Wang Q, Liu Q, Sun Q, Chen L. N-acetylcysteine prevents orchiectomy-induced osteoporosis by inhibiting oxidative stress and osteocyte senescence. Am J Transl Res. 2019 Jul 15;11(7):4337-47.

30. Jeddi S, Yousefzadeh N, Kashfi K, Ghasemi A. Role of nitric oxide in type 1 diabetes-induced osteoporosis. Biochem Pharmacol. 2022 Mar;197:114888. https://doi.org/10.1016/j.bcp.2021.114888

31. Hu XF, Xiang G, Wang TJ, Ma YB, Zhang Y, Yan YB, Zhao X, Wu ZX, Feng YF, Lei W. Impairment of type H vessels by NOX2-mediated endothelial oxidative stress: critical mechanisms and therapeutic targets for bone fragility in streptozotocin-induced type 1 diabetic mice. Theranostics. 2021 Jan 30;11(8):3796-812. https://doi.org/10.7150/thno.50907

32. Korokin MV, Soldatov VO, Gudyrev OS. The role of cortisol metabolism in the realization of pathogenetic links in the development of osteoporosis - the rationale for the search for new pharmacotherapeutic targets (review). Research Results in Biomedicine. 2022;8(4):457-73. https://doi.org/10.18413/2658-6533-2022-8-4-0-5